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inhibited glioma cell proliferation in a dose dependent 
manner, demonstrated by MTS assay, manual cell count 
and BrdU incorporation. A dose dependent increase in 
apoptosis was observed through flow cytometric analysis. 
Furthermore, by immunocytochemistry and western blot, 
we found a dose dependent inhibition of Akt phosphoryla-
tion. Moreover, buparlisib prolonged survival of nude rats 
harboring human GBM xenografts in three independent 
studies and reduced the tumours’ volumetric increase, as 
determined by MRI. In addition, histological analyses of 
xenograft rat brains showed necrotic areas and change in 
tumour cell nuclei in buparlisib-treated animals. The rats 
receiving buparlisib maintained their weight, activity level 
and food- and water intake. In conclusion, buparlisib effec-
tively inhibits glioma cell proliferation in vitro and growth 
of human GBM xenografts in nude rats. Moreover, the 
compound is well tolerated when administered at doses 
providing anti-tumour efficacy. Thus, buparlisib may have 
a future role in glioma therapy, and further studies are war-
ranted to validate this compound for human use.
Keywords Glioblastoma · Brain tumours· PI3K · 
Proliferation · Targeted therapy · Patient-derived 
xenograft
Introduction
Glioblastoma (GBM) is the most aggressive primary brain 
tumour [1] with a medi n survival of 14.6 months. Less than 
10 % of patients survive 5 years after diagnosis [2]. The di-
mal progno s f r GBM patients, despite multimodal treat-
ment calls for new therapeutic strategies.
Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases 
involved in cell proliferation, growth, apoptosis, DNA 
Abstract Glioblastomas (GBMs) are aggressive br in 
tumours with a dismal prognosis, despite combined sur-
gery, radio- and chemotherapy. Close to 90 % of all GBMs
harbour a deregulated PI3K p thway, which is essential 
in regulating central cell lar functions such as prolifera-
tion, cell growth, motility and survival. Thus, PI3K rep-
resents a potential target f r m l cular therapy in GBM. 
We investigated the anti-tumour efficacy of the PI3K 
inhibitor buparlisib (NVP-BKM120) in GBM cell lin s in 
vitro and in vivo, when treatm nt was initiated after MRI-
confirmed tumour engraftment. We found that buparlisib 
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Materials and methods
Cell line and culturing
Cells were maintained in humid incubators at 37 °C and 
5 % CO2. The U87 cell line was purchased from American 
Type Culture Collection (ATCC, Manassas, VA, USA) and 
cultured in DMEM (Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 10 % fetal bovine serum, 3.2 % non-
essential amino acids, 100 units/mL Penicillin/Streptomy-
cin, 400 mol/L l-glutamine (all Lonza, Cologne, Germany) 
and 0.005 mg/mL Plasmocin (InvivoGen, San Diego, CA, 
USA). Prior to animal implantation, spheroids of U87 cells 
were prepared; 1000 cells were centrifuged at 2250 rpm 
for 30 min in 96-well plates with conical bottom, contain-
ing 0.05 % methylcellulose. After 7 days incubation, each 
spheroid contained 17,000 cells. Three spheroids (51,000 
cells) were implanted in each animal. For in vitro assess-
ment of buparlisib efficacy, a 10 mM stock solution was pre-
pared by dissolving buparlisib [kindly provided by Novartis 
(Basel, Switzerland)] in 100 % DMSO (Sigma-Aldrich).
Patient tumour material and culturing
Tumour biopsy tissue was obtained from the operating the-
atre, Haukeland University Hospital, Bergen, after approval 
from the regional Ethical Board and consent from patients. 
Xenograft spheroids (P3) were prepared from serially pas-
saged GBM biopsy tissue (as described by Wang [10]) 
and cultured as described by Bjerkvig [11]. Prior to ani-
mal implantation, the spheroid material was enzymatically 
dissociated at 37 °C by trypsin-EDTA and DNase (Roche, 
Basel, Switzerland) and resuspended in sterile PBS with 
25 mM glucose (both Sigma-Aldrich). 100,000 cells were 
implanted in each animal. For in vitro experiments, the 
spheroid material was grown in monolayer and maintained 
in NB medium (Thermo Fisher Scientific Corporation, 
Carlsbad, CA, USA) with the addition of 32 IE/mL heparin, 
20 ng/mL bFGF and 20 ng/mL EGF (Millipore Corporation, 
Billerica, MA, USA).
Cell viability (MTS assay)
Cells were seeded in 96-well plates 24 h prior to treat-
ment with buparlisib at concentrations ranging from 0 to 
10 mM. After 72 h of exposure, the cells were subjected to 
MTS viability assay according to the manufacturer’s pro-
tocol (CellTiter 96® AQ ueous One Solution Cell Prolifera-
tion Assay, Promega, Madison, WI, USA). Dose response 
curves for determination of IC50 values were generated in 
GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, 
USA).
repair, angiogenesis, differentiation, motility and survival 
[3]. PI3Ks act as intermediate signaling molecules, involved 
in cell signaling pathways such as the PI3K/Akt/mTOR [4]. 
In normal cells, the PI3K activity is tightly regulated. Dereg-
ulation of the PI3K signaling pathway is common in ca cer, 
including GBM [5]. Brennan and colleagues report d muta-
tions in PI3K in 25.1 % of GBMs, whereas 89.6 % of GBMs 
had at least one alteration in th  PI3K pathway inc ud ng its 
other components, such as RTKs and PTEN [6]. Ac ivat on
of this pathway is associated wi h increasing tumour grade 
and decreasing overall surv val in gliomas [7]. The initial 
step in the PI3K pathway is PI3K-mediated phosphoryla-
tion of membrane bound phosphatidylinos to s, gener-
ing second messengers (PIP3, PI 3,4-bisphosphate), which 
subsequently trigger a signaling cascade eventually activat-
ing multiple effector kinase pathwa s, such a  the mTOR,
ERK1/2, p38 MAPK, NF-kappa-B, and JNK/SAPK [4]. A
key event in this cascade is binding of PIP3 to Akt, which 
is activated by phosphorylation at S473 and T308 [8]. The 
activation of Akt is assumed to be responsible for its growth-
promoting and anti-apoptotic effects in tumour cells [4].
Given its role as a major regulator of multiple aspects of 
tumour cell behavior, PI3K has become a major a get for 
drug design. Several small molecule PI3K inhibitors have 
been developed and are currently under pre-clinical and 
clinical assessment [4]. However since the blood–brain-bar-
rier (BBB) limits availability of drugs t  the central ne vous 
system (CNS), brain tumours ar  generally not considered
attractive malignancies for initial drug screenings. For the 
same reason, few animal studies and hardly any patient tri-
als have been published regarding the anti-tumour efficacy 
of PI3K inhibitors in gliomas.
Buparlisib (NVP-BKM120) is an ora ly bioavailable, 
small molecule compound with potent, pan-class I PI3K 
inhibitory capability against the p110-α, -β, -δ, d -γ cata-
lytic subunit isoforms at IC50 doses in a m cromolar ra ge 
[9]. Since buparlisib penetrates the BBB [9], t represents 
an attractive candidate for targeted glioma therapy. Previ-
ously, Koul et al. reported inhibitio  of cell line derived 
brain tumour growth in SCID mice us ng buparlisib admin-
istered 4 days following implantation of the tumour cells. 
In the clinical setting, therapy s usually initi ted after the 
tumour is confirmed by MRI and biopsy. Here we demon-
strate efficacy of buparlisib in treatment of patient derived 
in vivo passaged GBM biopsy aterial in the experimental 
setting resembling the usual clinical situati n with tumour 
confirmed by MRI. The in vivo passaged GBM biopsies 
develop tumours that histol gically clos ly resembl  the 
GBM in situ [10]. The aim of the present study was to evalu-
ate the efficacy of buparlisib treatment, initiated after con-
firming tumour engraftment by MRI in a clinically relevant 
brain tumour animal model [10].
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Immunoblotting (western blot)
Cells and tissue were harvested in kinexus buffer [20 mM 
MOPS, 5 mM EDTA, 2 mM EGTA, protease and phos-
phatase inhibitor tablets (Roche)], followed by sonication 
3 × 5 s. Protein concentrations were determined by Pierce 
BCA Protein Assay Kit (Thermo Fisher Scientific Corpora-
tion). 20 mg sample was mixed with LDS sample loading 
buffer and sample reducing agent (both NuPAGE, Thermo 
Fisher Scientific Corporation) and incubated at 70 °C for 
10 min. Samples were run on a pre-cast NuPAGE SDS-gel 
(Thermo Fisher Scientific Corporation) at 200 V for 60 min. 
Transfer to a nitrocellulose membrane was done at 30 V f r 
80 min. Following blocking in 5 % (w/w) Difco Skim milk 
powder (Becton, Dickinson and Company, Franklin Lakes, 
NJ, USA), in TBST for 1 h at RT, the membranes were incu-
bated with primary antibody (total Akt, pAkt S473, pAkt 
T308) and β-actin (Santa Cruz Biotechnology Inc, Dallas, 
TX, USA) or GAPDH (Abcam) at 4 °C O/N. After wash-
ing, membranes were incubated with secondary antibodies 
[goat anti-mouse IgG-HRP (Santa Cruz Biotechnology Inc) 
and goat anti-Rabbit IgG (H+L) Cross Adsorbed Secondary 
Antibody, HRP conjugate (Thermo Fisher Scientific Cor-
poration)] for 1.5 h at RT. For detection, Supersignal West 
Femto Maximum Sensitivity Substrate (Pierce Biotechnol-
ogy, Rockford, IL, USA) was used, and chemiluminescent 
detection was obtained by a Fuji LAS 3000 Imager (Fuji 
Photo Film, Tokyo, Japan). Densitometric quantification 
was determined using ImageJ software (National Institutes 
of Health, Bethesda, MA, USA).
Immunohistochemistry (IHC)
Paraffin-embedded sections from P3 xenograft rat brains 
were deparaffinised using xylene, 100 and 96 % ethanol, 
followed by antigen retrieval at 98 °C for 25 min in 10 mM
citrate buffer, pH 6.0. Sections were treated with peroxi-
dase and protein block (both Dako, Glostrup, Denmark) for 
5 and 30 min, respectively. The primary antibody mouse 
anti-nestin (Millipore Corporation) was diluted to 1:1000 in 
Tris–BSA buffer, and added to the slides for 1 h at room 
temperature. Following washing with TBS-Tween, sec-
tions were incubated with anti-mouse secondary antibody 
(Dako) for 45 min at room temperature. Slides were devel-
oped with DAB chromogen (Dako) and counterstained with 
hematoxylin.
Animals
Homozygous nude rats (rnu/rnu, Rowett) were used for the 
experiments. The animals were fed a standard pellet diet 
and provided water ad libitum, and kept in a pathogen free 
Cell count
Cells were seeded 24 h prior to exposure of buparlisib for 
72 h, before enzymatically detached by Trypsin–EDTA 
solution (Sigma-Aldrich), and m nually coun ed in a Burker 
chamber haemocytometer.
BrdU-pulsing
Cells exposed to buparlisib for 72 h were trea ed with 
10 mM BrdU (Sigma-Aldrich) for 45 m n at 37 °C. They 
were detached using a cell scraper, washed with 1xPBS 
and resuspended to 1 × 105 c lls/mL. 100 mL cell suspen-
sion was loaded into individual samp e cham ers a d cen-
trifuged in a Shandon CytoSpin c ntrifuge (Thermo Fisher
Scientific, Wilmington, DE, US) at 800 rpm for 3 min. 
Immobilized cells were fixed (ICC-section) and subse-
quently subjected to immunocytochemis ry, imaging and 
quantification. For each slide, three randomly picked areas 
(832 × 665.6 mM, 554 mM2) were selected for quantifica-
tion. FITC stained cells and tot l number of cells w s man-
ually counted, and the proporti n of FITC positive cells 
was calculated.
Annexin V/propidium iodide (PI) apoptosis assay
Cells were stained with the Annex n V poptos s assay 
according to the manufacturer’s protocol (Thermo F sher 
Scientific). Samples were analysed on Accuri C6 (BD Bio-
sciences) flow cytometer.
Immunocytochemistry (ICC)
Cells were fixed in 4 % paraformaldehyde (Thermo Fisher 
Scientific Corporation) for 10 min, permeabilized by 0.5 % 
Triton X-100 (Sigma-Aldrich) in PBS for 4 min and incu-
bated with blocking buffer [0.5 % BSA (Sigma-Aldrich) in
PBS] for 15 min. Cells were incubate with primary anti-
bodies O/N at 4 °C. The primary antibodies used were total 
Akt, pAkt S473, pAkt T308 (all Cell Sig aling Technol gy, 
Danvers, MA, USA), and BrdU (Abcam, Cambridge, UK) 
together with DNase (Roche). Following incubatio , cells 
were washed in PBS and incubated ith se ondary an i-
bodies for 45 min at 37 °C. The secondary antibodies used 
were FITC-conjugated [S473; goat ant -rabbit (Southern 
Biotechnologies Associates Inc., Birmingham, AL, USA)] 
or AF555-conjuagted [Total Akt; goat anti-mouse (Thermo 
Fisher Scientific)]. Cells were mounted with Vectashield 
mounting medium with DAPI (Vector Laboratories, Burl-
ingame, CA, USA). Fluorescent images were obtained with 
a Nikon TE2000-E microscope (Nikon Corporation, Tokyo, 
Japan).
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MTS assay. IC50 doses were found to be 1.17 and 0.84 mM 
for U87 and P3 cells, respectively (Fig. 1a). To test the 
side effects of the drug on non-tumor cells, glial cells from 
NOD/SCID mice brains were sorted and cultured in vitro, 
subsequently treated with 1 or 10 mM of buparlisib. After 
72 h of exposure, treated cells and controls were analysed 
using the MTS assay. These data demonstrated that the met-
abolic activity of normal brain cells was significantly less 
affected than the P3 and U87 glioma cells (Supplementary 
Fig. 1). Furthermore, manual cell counting (Fig. 1b) showed 
that buparlisib reduced cell numbers in a dose dependent 
manner for both U87 and P3. In order to determine whether 
this reduction reflected increased cell death, decreased pro-
liferation or both, untreated and buparlisib-treated cells 
were pulsed with the S-phase marker BrdU. Quantification 
of BrdU positive cells revealed a dose dependent decrease 
in cell proliferation (Fig. 1c), suggesting an anti-prolifer-
ate effect of buparlisib. The solvent (DMSO) did not show 
anti-proliferative effect (data not shown). Interestingly, flow 
cytometry of PI/Annexin V-stained cells demonstrated a 
dose-dependent increasing apoptosis upon buparlisib-treat-
ment (Fig. 1d).
Buparlisib inhibits phosphorylation of Akt in vitro
The inhibitory effect of buparlisib on PI3K was shown by 
decreased activating phosphorylation of the PI3K down-
stream effector Akt. Akt is activated by phosphorylation of 
the amino acid residues threonine 308 (T308) and serine 
473 (S473). ICC of U87 cells on coverslips, fixated after 
exposure of buparlisib for 72 h demon trated a dose depen-
dent reduction of Akt phosphorylation (Fig. 2a). Quantita-
tive analysis was performed by western blot of lysates from 
U87 (Fig. 2b) and P3 (Fig. 2c) cells exposed to buparlisib 
in various concentrations and band intensities were assessed 
by densitometry. A dose dependent reduction of Akt phos-
phorylation at both sites (S473 and T308) was observed. 
Treatment with buparlisib did not alter the total level of Akt 
protein, indicating that the reduced level of phosphorylated 
Akt was caused by an inhibition of its phosphorylation and 
not by decrease of the Akt protein level.
Buparlisib reduces tumour growth and prolongs 
survival in nude rats harbouring GBM xenografts
The anti-tumour efficacy of buparlisib in vivo was evalu-
ated in a clinically relevant GBM animal model that uses 
intracerebrally engrafted in vivo passaged GBM xenografts 
derived from human biopsy material. This model reflects the 
growth pattern of human tumours in situ, including infiltra-
tion into the brain parenchyma and angiogenesis [10]. Three 
weeks after implantation of the tumour, MRI confirmed 
tumour take, and the animals were randomly assigned to 
environment at a constant temper ture and humidity with 
standard 12/12 h light and dark cycle. The experiment was 
approved by the Norwegian An mal Research Authority 
(Bergen, Norway). All animals were ana sthetized with 3 % 
isoflurane gas (Abbott Laboratories, Abbot Park, IL, USA) 
mixed with 50 % air and 50 % O2, and Marcaine (AstraZ n-
eca, London, England) subcutaneously. umour implan-
tation was performed as prev ously described [10]. Three 
animal studies were performed, and tre tment st rted imme-
diately after confirmed tumour take by MRI (U87 sper-
oids; 10 days, P3 cell suspension; 21 days). Animals were 
randomly assigned to two different groups: (1) untreate  
controls and (2) 5 mg/kg bupa lisib tr tmen ( ecom-
mended by Novartis). Buparlisib suspe sion was prepared 
in 0.5 % methyl cellulose and 0.5 % Tween20 (both Sigma-
Aldrich), while control group received vehicl  only (0.5 % 
methyl cellulose and 0.5 % Twe n20). Both groups we e 
treated 5 days a week and received 10 mL/kg solution by 
oral gavage, using malleable oral dosing needl s (Scanbur, 
Karlslunde, Denmark). Animals were weighed five times a 
week, inspected daily and euthanized by CO2 inhalation at 
the onset of symptoms.
Magnetic resonance imaging (MRI)
MRI scans of all animal brains were ob ained after tumour 
implantation to assess the tumour grow h us a Bruker 
Pharmascan 7T small animal MRI (Bruk r Biospin MRI 
GmnH, Ettingen, Germany). Axial T1- and T2-weighted 
images were obtained as previously described [10]. The 
tumour volumes at treatment and follow-up MRI were cal-
culated in Gamma Plan (Elekta Ins rument AB, Stockholm, 
Sweden).
Statistical analysis
In vitro experiments were repeated hree imes and a sessed 
by ANOVA with Tukey’s multiple comparions est, with a p
value <0.05 considered significant. Kaplan–Meier survival 
curves were generated in GraphP d Prism 6 (GraphPad 
Software Inc.) for statistical analysis of the animal experi-
ments. Median survival times for the treatment groups were 
compared using the log-rank test.
Results
Buparlisib inhibits cell grow h and induces apoptosis of
GBM cells
The cytotoxic potential of buparlisib on GBM cells was 
determined by exposing P3 GBM xenogr f  cells and U87 
cells to buparlisib for 72 h, and assessing viability using the 
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n =3) and 45 days (range 43–46 days, n = 3) in the treatment 
and control group respectively (p = 0.0246, Fig. 3b). MRI 
2 weeks after treatment initiation revealed significantly 
smaller tumour volumes in the treatment group [20.2 mM2 
versus 103.4 mM2 for the control group (Fig. 3c)]. Histol-
ogy showed necrotic tumour areas in all four animals ana-
lysed from the treated group, while only one out of four 
animals from the control group showed a small necrotic 
tumour area (Fig. 3d). Furthermore, the density of tumour 
two treatment groups: one receiving 5 mg/kg buparlisib for
5 consecutive days and 2 days rest, and one group receiving 
vehicle only (control).
In the first study, the median survival from implantation 
was 36 days (range 31–40 days) for the buparlisib-treated 
rats (n = 5), and 30 days (range 29–35 days) for the con-
trol rats (n = 4) (p = 0.039) (Fig. a). The survival benefit 
was confirmed in a second study with a median survival 
from tumour implantation of 51 days (range 50–54 days, 
Fig. 1 a IC50 doses of buparl-
isib for P3 (left) and U87 (right) 
glioma cells. b Relative cell 
number of P3 (left) and U87 
(right) glioma cells exposed to 
buparlisib for 72 h. c Quantifi-
cation of BrdU positive P3 (left) 
and U87 (right) glioma cells 
treated with buparlisib for 72 h 
with doses as indicated, and 
subsequently pulsed with BrdU. 
d Quantification of Annexin 
V- and PI-positive P3 (left) 
and U87 (right) glioma cells 
treated with buparlisib for 72 h 
with doses as indicated, and 
subsequently incubated with PI 
and Annexin V Alexa Fluor 488 
conjugate. Error bars represent 
SEM. Red bars indicate p val-
ues for linear trends. All experi-
ments were performed three 
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Fig. 2 a Immunocytochemistry showing Akt phosphorylation in U87-
cells at S473 after exposure to different concentrations of buparlisib 
for 72 h. Upper panel overlay image of Akt phosphorylated at site 
S473 (FITC, green) and total Akt (AP555, red) with DAPI nuclear 
counterstaining (blue). Middle pan l 1 DAPI nuclear staining (blue). 
Middle panel 2 Akt phosphorylated at site S473 (FITC, green). Lower 
panel total Akt-levels (AP555, red). bLeft western blots showing lev-
els of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed 
to buparlisib for 72 h. Right densitometric assessment of western 
blots, showing relative changes in phosphorylation. cLeft western 
blots showing levels of pAkt (T308), pAkt (S473) and total Akt in 
P3 cells exposed to buparlisib for 72 h. Right densitometric assess-
ment of western blots, showing relative changes in phosphorylation. 
Error bars represent SEM of three independent experiments. p values 
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buparlisib treatment after tumour engraftment was veri-
fied by MRI (10 days post implantation). In this study, the 
median survival in the control group (n = 9) was 25.5 days 
(range 19–39 days) from implantation versus 30 days (range 
24–67 days) in buparlisib-treated rats (n = 9) (p = 0.0097, 
Fig. 4a). Notably, in the treatment group, some animals lived 
several weeks longer than untreated animals. MRI scans 
performed weekly revealed stable tumour volume, indi-
cating prolonged progression free survival in the animals 
responding to the therapy (Fig. 4c). However, after the initial 
response, the tumours resumed growth and the animals devel-
oped symptoms.
cell nuclei seemed to be reduced in the treated compared 
to control tumours. As the intermediate filament protein 
nestin is expressed in a very high f action of tumour ce ls, 
we used it as a tumour marker. Immunostaining for nestin 
revealed that the morphology of tumour cells changed in 
the treated animals compared to c ntrols. Tumour cells from 
the treated group showed a more epithelial-like p e otype 
while the tumour cells of th  c ntrol tumours had a me en-
chymal shape which was best visible in infiltrative tumour 
areas (Fig. 3d).
To confirm previous findings in a larger study we ste-
reotactically implanted U87 glioma s heroids and initiated 
Fig. 3 a Kaplan–Meyer survival curve for first study with nude rats 
carrying P3 xenografts (n = 9). b Kaplan–Meyer survival curve for the 
second study, with nude rats carrying P3 xenografts (n = 6). c MRI-
based assessments of tumour volumes 3 weeks post implantation 
(treatment start) and 5 weeks post implantation. *p <0.05. d H&E and 
nestin immunos ained sections of treated and control tumors. Arrows 
ind cate a ec otic tumour area. Scale bars 50 μm
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of Akt phosphorylation at both serine 473 (S473) and threo-
nine 308 (T308) was demonstrated. In vivo, buparlisib treat-
ment led to significantly improved survival and reduced 
tumour volume. The compound seemed to be well tolerated 
by the animals, also during prolonged treatment over sev-
eral weeks.
The observed in vitro anti-proliferative effect of buparl-
isib confirms previous findings, which include cell lines of 
glioma origin [9, 12], as well as other cell lines [9]. The abil-
ity of buparlisib to induce apoptosis as well as dose depen-
dent reduction of Akt phosphorylation in vitro both at S473 
and T308 is in line with previous reports [9, 13].
In our study, buparlisib demonstrated anti-tumour effi-
cacy in an animal model employing patient-derived tumour 
material that was previously shown to mimic the growth 
of human gliomas in situ [14]. The three independent ani-
mal experiments confirmed previous reports of prolonged 
survival of animals with intracranial GBM xenografts [9]. 
However the efficacy of buparlisib in GBM therapy has not 
previously been studied using in vivo propagated patient-
derived tumour material. Our results were further validated 
with a commonly used glioma cell line U87 [15]. However, 
we initiated buparlisib treatment up to 3 weeks following 
tumour implantation, after tumour engraftment was con-
firmed by MRI. Although, Koul et al. reported growth inhi-
bition in an in vivo GBM model using buparlisib [9], they 
Buparlisib inhibits phosphorylation of Akt in vivo
Ex vivo western blot analysis of tumour ti sues from eutha-
nized rats showed significant inhibition of Akt phosphory-
lation at S473. Phosphorylation at T308 w s also re ced 
following treatment, although this difference was not signifi-
cant. The total level of Akt protein was unchanged (Fig. 5a, b).
Daily treatment with buparlis b in nude rats 
harbouring GBM xenografts is well tole ated
Daily inspection of the rats showed no cha ge of activity 
or food and water intake. Thro ghout th  exper ment, both 
the treated and control animals showed st ble body weight, 
although the treatment group displayed a light weight 
reduction (Fig. 5c). The rats in the treatment group had tem-
porary hair loss after 3 weeks of treatment. However, the 
animals exhibited hair re-growth while they were st ll on 
treatment. No severe side effects were ob erved.
Discussion
We evaluated the anti-tumour efficacy of pan-PI3K inhibi-
tor buparlisib on glioma. A dose dependen  an i-prolifera-
tive effect of buparlisib in v tro, accompan ed by inhibit on
Fig. 4 a Kaplan–Meyer survival curve for nude rats carrying ortho-
topic GBM cell line (U87) xenografts (n = 18).b MRI-based a sess-
ments of tumour volumes 10 days post implantation (treatment start) 
and 24 days post implantation. *p <0.05 c T1-we ghted magnetic reso-
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intracranial target. This is in line with the published study 
of Koul and colleagues [9] and the previously reported 
BBB penetrance [9]. The histopathology of the tumours 
was altered in the treated animals indicating the therapeutic 
effect of the compound. Moreover, buparlisib seemed to be 
well tolerated by the animals, also over a prolonged expo-
sure time. Similar observations have been made in phase I/
II clinical studies of buparlisib [17–19].
Treatment resistance in cancer is commonly mediated 
through activation of the PI3K pathway [20]. Targeting PI3K 
may thus be a plausible strategy for treatment of GBM. Pre-
vious studies demonstrated that inhibition of PI3K increases 
the sensibility of GBM cells to doxorubicin treatment in 
vitro [21]. Buparlisib has demonstrated an additive effect 
when combined with temozolomide in glioma cells, and 
a synergistic effect when combined with MEK and HER2 
inhibitors [9]. Here we show anti-tumour efficacy of a PI3K 
inhibitor alone. The secondary resistance to PI3K inhibitor 
might be attenuated by combining buparlisib with conven-
tional chemotherapy. Currently, there are ongoing clinical 
initiated treatment shortly afte  tumour implantation with-
out prior confirmation of tumour engraftment. We believe 
our present data obtained in a model closely resembling 
the clinical setting where the relapsed tumou  is detected 
by MRI, provide additional suppor for clinical validation 
of buparlisib for human GBMs. Interestingly, the observed 
anti-tumour efficacy of buparlisib extends beyond previ-
ous results, as one third of the animals experienced pro-
longed progression free surviv l a d even slight reduction 
in tumour size for several weeks. However, the e fect was 
temporary as the tumours eventually resumed growth. This 
reflects the palliative therapy of solid tumours, when tumour 
progression occurs after initial volume response and/or dis-
ease stabilization. Bradford et al. have also reporte  devel-
opment of secondary resistance t  uparlisib herapy. In 
endometrial cancer the resista ce was mitigated by conven-
tional chemotherapy [16].
Ex vivo analysis of the tumour samples obtained post 
mortem from treated animals demonstra d decreased phos-
phorylation of Akt, confirming that buparlisib does reach its 
Fig. 5 a Western blots showing levels of pAkt (T308), pAkt (S473) 
and total Akt in the tumours of one representative U87-xenografted rats 
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trials assessing buparlisib monotherapy in recurren  GBM 
as well as of combination of buparlisib with other agents in 
newly diagnosed and recurrent malignant glioma.
In conclusion, we have shown that bupar isib has ant -
tumour efficacy as a monotherapy in preclinical studies. 
Thus, we believe our data provide a rationale for clinical 
trials validating buparlisib as a single therapy in GBM 
patients.
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